Literature DB >> 11834491

Cardiac overexpression of A1-adenosine receptor protects intact mice against myocardial infarction.

Zequan Yang1, Rachael J Cerniway, Anne M Byford, Stuart S Berr, Brent A French, G Paul Matherne.   

Abstract

Previous studies have shown that high-level (300-fold normal) cardiac overexpression of A1-adenosine receptors (A1-ARs) in transgenic (TG) mice protects isolated hearts against ischemia-reperfusion injury. However, this high level of overexpression is associated with bradycardia and increased incidence of arrhythmia during ischemia in intact mice, which interfered with studies to determine whether this line of TG mice might also be protected against myocardial infarction (MI) in vivo. For these studies, we therefore selected a line of TG mice that overexpresses the A1-AR at more moderate levels (30-fold normal), which affords cardioprotection in the isolated heart while minimizing bradycardia and arrhythmia during ischemia in intact mice. Wild-type (WT; n = 10) and moderate-level A1-AR TG (n = 10) mice underwent 45 min of left anterior descending coronary artery occlusion, followed by 24-h reperfusion. Infarct size and region at risk were determined by triphenyltetrazolium chloride and phthalo blue staining, respectively. Infarct size (% region at risk) in WT mice was 52 +/- 3%, whereas overexpression of A1-ARs in the TG mice markedly reduced infarct size to 31 +/- 3% (P < 0.05). Furthermore, contractile function (left ventricular ejection fraction) as determined by cardiac magnetic resonance imaging 24 h after MI was better preserved in TG vs. WT mice. Cardiac overexpression of A1-ARs reduces infarct size by 40% and preserves cardiac function in intact mice after MI.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11834491     DOI: 10.1152/ajpheart.00741.2001

Source DB:  PubMed          Journal:  Am J Physiol Heart Circ Physiol        ISSN: 0363-6135            Impact factor:   4.733


  21 in total

1.  Transgenic over expression of ectonucleotide triphosphate diphosphohydrolase-1 protects against murine myocardial ischemic injury.

Authors:  Ming Cai; Zachary M Huttinger; Heng He; Weizhi Zhang; Feng Li; Lauren A Goodman; Debra G Wheeler; Lawrence J Druhan; Jay L Zweier; Karen M Dwyer; Guanglong He; Anthony J F d'Apice; Simon C Robson; Peter J Cowan; Richard J Gumina
Journal:  J Mol Cell Cardiol       Date:  2011-09-12       Impact factor: 5.000

Review 2.  G Protein-coupled Receptor Biased Agonism.

Authors:  Sima Y Hodavance; Clarice Gareri; Rachel D Torok; Howard A Rockman
Journal:  J Cardiovasc Pharmacol       Date:  2016-03       Impact factor: 3.105

Review 3.  Current status of cardiac MRI in small animals.

Authors:  J-P Vallée; M K Ivancevic; D Nguyen; D R Morel; M Jaconi
Journal:  MAGMA       Date:  2004-12-16       Impact factor: 2.310

Review 4.  Adenosine receptors as therapeutic targets.

Authors:  Kenneth A Jacobson; Zhan-Guo Gao
Journal:  Nat Rev Drug Discov       Date:  2006-03       Impact factor: 84.694

5.  Cardiac-restricted overexpression of the A(2A)-adenosine receptor in FVB mice transiently increases contractile performance and rescues the heart failure phenotype in mice overexpressing the A(1)-adenosine receptor.

Authors:  Tung O Chan; Hajime Funakoshi; Jianliang Song; Xue-Qian Zhang; JuFang Wang; Paul H Chung; Brent R DeGeorge; Xue Li; Jin Zhang; David E Herrmann; Maura Diamond; Eman Hamad; Steven R Houser; Walter J Koch; Joseph Y Cheung; Arthur M Feldman
Journal:  Clin Transl Sci       Date:  2008-09       Impact factor: 4.689

Review 6.  Adenosine receptors and reperfusion injury of the heart.

Authors:  John P Headrick; Robert D Lasley
Journal:  Handb Exp Pharmacol       Date:  2009

Review 7.  Cardiac purinergic signalling in health and disease.

Authors:  Geoffrey Burnstock; Amir Pelleg
Journal:  Purinergic Signal       Date:  2014-12-20       Impact factor: 3.765

8.  Separation of on-target efficacy from adverse effects through rational design of a bitopic adenosine receptor agonist.

Authors:  Celine Valant; Lauren T May; Luigi Aurelio; Chung Hui Chuo; Paul J White; Jo-Anne Baltos; Patrick M Sexton; Peter J Scammells; Arthur Christopoulos
Journal:  Proc Natl Acad Sci U S A       Date:  2014-03-11       Impact factor: 11.205

9.  Cardiac myocyte-secreted cAMP exerts paracrine action via adenosine receptor activation.

Authors:  Yassine Sassi; Andrea Ahles; Dong-Jiunn Jeffery Truong; Younis Baqi; Sang-Yong Lee; Britta Husse; Jean-Sébastien Hulot; Ariana Foinquinos; Thomas Thum; Christa E Müller; Andreas Dendorfer; Bernhard Laggerbauer; Stefan Engelhardt
Journal:  J Clin Invest       Date:  2014-11-17       Impact factor: 14.808

10.  Activation of A1, A2A, or A3 adenosine receptors attenuates lung ischemia-reperfusion injury.

Authors:  Leo M Gazoni; Dustin M Walters; Eric B Unger; Joel Linden; Irving L Kron; Victor E Laubach
Journal:  J Thorac Cardiovasc Surg       Date:  2010-04-15       Impact factor: 5.209

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.